Vanguard Group Inc. Acquires 56,723 Shares of Repligen Co. (NASDAQ:RGEN)

Vanguard Group Inc. grew its holdings in Repligen Co. (NASDAQ:RGEN) by 1.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,101,090 shares of the biotechnology company’s stock after acquiring an additional 56,723 shares during the period. Vanguard Group Inc. owned 9.10% of Repligen worth $734,251,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. LPL Financial LLC increased its position in Repligen by 47.6% during the fourth quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company’s stock worth $4,873,000 after buying an additional 10,395 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Repligen during the 4th quarter worth about $667,000. KLP Kapitalforvaltning AS acquired a new position in shares of Repligen during the 4th quarter valued at about $1,555,000. Sei Investments Co. raised its stake in shares of Repligen by 12.7% in the 4th quarter. Sei Investments Co. now owns 219,604 shares of the biotechnology company’s stock valued at $31,610,000 after acquiring an additional 24,662 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Repligen in the 4th quarter worth approximately $251,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 1.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Canaccord Genuity Group lifted their price target on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Evercore ISI started coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 target price for the company. StockNews.com downgraded Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. Royal Bank of Canada boosted their price objective on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research report on Friday, February 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $180.00 target price on shares of Repligen in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $178.64.

Repligen Stock Down 2.7 %

Shares of RGEN opened at $133.41 on Monday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average price of $154.21 and a two-hundred day moving average price of $148.19. The stock has a market cap of $7.49 billion, a price-to-earnings ratio of -261.59, a P/E/G ratio of 4.54 and a beta of 0.95. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $184.98.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Equities analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.